Author

M. Raab

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

K. Strebhardt· 3 shared A. C. Joerger· 2 shared A. Poso· 2 shared L. M. Berger· 2 shared M. Rak· 2 shared M. Sanhaji· 2 shared R. Tesch· 2 shared S. Knapp· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

K. Strebhardt

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Shifting the selectivity of pyridopyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

M. Rak, R. Tesch, L. M. Berger, E. Shevchenko, M. Raab, A. Tjaden, R. Zhubi, D.-I. Balourdas, A. C. Joerger, A. Poso, A. Kraemer, L. Elson, A. Lucic, T. Kronenberger, T. Hanke, , S. Knapp

This paper develops a selective SIK kinase inhibitor, MR22, by optimizing a pyrido[2,3-d]pyrimidin-7(8H)-one scaffold to eliminate PAK activity, demonstrating its efficacy in ovarian cancer cells.

European Journal of Medicinal Chemistry · Jun 1, 2023Peer-reviewedBiochemistry

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

R. Lutz, F. Gruenschlaeger, M. Simon, M. Bauer, S. Yousefian, N. Beumer, L. Jopp-Saile, M. Awwad, G. Steinbuss, A. Sedlmeier, T. Boch, D. Vonficht, M.-A. Baertsch, B. Durie, N. Weinhold, , S. Haas

This study examines immune changes in multiple myeloma survivors years after treatment, finding sustained immune alterations linked to residual disease and therapy.

bioRxiv · May 27, 2023 · PreprintCancer Biology

Structure-based design of selective salt-inducible kinase (SIK) inhibitors

R. Tesch, M. Rak, M. Raab, L. M. Berger, T. Kronenberger, A. C. Joerger, B. T. Berger, I. Abdi, T. Hanke, A. Poso, K. Strebhardt, M. Sanhaji, S. Knapp

This study designs a selective SIK inhibitor, MRIA9, based on a PAK inhibitor, showing its dual activity and potential for combination therapy in ovarian cancer.

bioRxiv · Apr 8, 2021 · PreprintBiochemistry

Inhibition of PLK1-dependent EBNA2 phosphorylation promotes lymphomagenesis in EBV-infected mice.

X. Zhang, P. Schuhmachers, A. Mourao, P. Giansanti, A. Murer, S. Thumann, C. Kuklik-Roos, S. Beer, S. M. Hauck, W. Hammerschmidt, R. Küppers, B. Küster, M. Raab, K. Strebhardt, M. Sattler, , B. Kempkes

The paper shows that inhibiting PLK1-dependent EBNA2 phosphorylation enhances EBNA2 activity, promoting lymphoma development in EBV-infected mice.

bioRxiv · Mar 29, 2021 · PreprintCancer Biology